Sutro Biopharma, a Phase 1 biotech developing immunotherapies for multiple myeloma and NHL, filed on Wednesday with the SEC to raise up to $75 million in an initial public offering.
The South San Francisco, CA-based company was founded in 2003 and booked $33 million in revenue for the 12 months ended June 30, 2018. It plans to list on the Nasdaq under the symbol STRO. Sutro Biopharma filed confidentially on June 1, 2018. Cowen and Piper Jaffray are the joint bookrunners on the deal. No pricing terms were disclosed.
